Tauriga Sciences Inc. Progresses Towards Launch of Its Topical Medicinal Cannabis Creams Branded as Topicanna

LOS ANGELES, Nov. 25, 2014 (GLOBE NEWSWIRE) — Tauriga Sciences, Inc. (TAUG) (“Tauriga” or “the Company”), a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today updated shareholders about the upcoming launch of its proprietary topical medicinal cannabis creams to be branded as Topicanna. Several steps remain until an official launch is practical, however management is working diligently to complete these important steps; such steps are crucial to both the long term success and viability of the product line. These steps include: qualifying and testing oil with high cannabidiol (CBD) content from licensed suppliers, selecting the oil and scaling up the manufacturing process. The Company is hopeful that it can successfully launch its Topicanna product line within the next 60 days.

Many people who have used topical cannabis creams have reported decreased musculoskeletal pain without narcotic effects. The Company is currently developing two distinct Topicanna products: one which will contain ingredients to better penetrate to the joints, and one that will contain ingredients that have been successfully used for dermatological conditions. Tauriga’s products will be offered in the United States (in compliance with all applicable medical marijuana regulations) and potentially in Japan pursuant to the recently announced MOU with Tokyo-based iFLOW Ltd (“iFLOW”). Medical marijuana law in Japan requires that products use oil that has been extracted from the stalk of the cannabis plant and that is necessarily higher in CBD and low in THC, hence providing potential wellness and healing properties without psychoactive effects.

Tauriga is also finalizing its formulation for its CannaCaviar soft gels using high-CBD, low-THC oil that has been extracted from the stalk of the cannabis plant. CannaCaviar is included in the recently announced MOU.

The Company is genuinely excited to complete these above-mentioned final steps that precede the launch of its Topicanna and soft gel products. The Company will take all necessary steps to ensure that it is always in compliance with the governing laws of each state, country and jurisdiction in which it plans to market its topical medicinal cannabis line. The Company plans to issue an additional press release to shareholders, once the product is complete and ready for launch.

In addition to the planned launch of the Topicanna and CannaCaviar lines, Tauriga is developing an e-commerce website (www.taurigastore.com) to sell its non-cannabis containing line of natural wellness dietary supplements. These natural supplements include IndiCalm, a relaxant and anxiolytic based on L-theanine; ClearNaze, a natural decongestant without stimulant or drowsiness effects; Satietiva, an amino acid-based appetite suppressant; and EndoCannabinoid Omega-3 Support (or MendOCan), a highly pure, potent and palatable Omega 3 supplement. Interested customers will be able to purchase these cannabis-free products online when the site is launched before the end of the year.

About Tauriga Sciences, Inc.:

Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues in the natural wellness sector and in developing a proprietary synthetic biology platform technology. The mission of the Company is to acquire and build a balanced portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company’s business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. Please visit the Company’s corporate website at www.tauriga.com.

 

DISCLAIMER:

Forward-Looking Statements: Except for statements of historical fact, this news release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG’s predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.
 
Contact:
Tauriga Sciences, Inc.:
Dr. Stella M. Sung,
Chairman and Chief Executive Officer
Tauriga Sciences, Inc.
www.tauriga.com
San Diego: + 1-858-353-5749
Montreal: + 1-514-840-3697
Email: ssung@tauriga.com

No Comments

Sorry, the comment form is closed at this time.